pharmaceutical investing Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
pharmaceutical investing Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
pharmaceutical investing Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
pharmaceutical investing Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
pharmaceutical investing Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
pharmaceutical investing Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
pharmaceutical investing Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
pharmaceutical investing European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
pharmaceutical investing FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
pharmaceutical investing U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
pharmaceutical investing FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
pharmaceutical investing Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Renforth Resources Launches Research Collaboration with Queen's University on Low-Carbon Recovery of Critical Metals from the Victoria Deposit
